BR112022001285A2 - Degradador seletivo do receptor de estrogênio - Google Patents

Degradador seletivo do receptor de estrogênio

Info

Publication number
BR112022001285A2
BR112022001285A2 BR112022001285A BR112022001285A BR112022001285A2 BR 112022001285 A2 BR112022001285 A2 BR 112022001285A2 BR 112022001285 A BR112022001285 A BR 112022001285A BR 112022001285 A BR112022001285 A BR 112022001285A BR 112022001285 A2 BR112022001285 A2 BR 112022001285A2
Authority
BR
Brazil
Prior art keywords
estrogen receptor
selective estrogen
receptor degrader
degradator
chromen
Prior art date
Application number
BR112022001285A
Other languages
English (en)
Portuguese (pt)
Inventor
Mohanbhai Panchal Bhavesh
Biswajit Samanta
Dilipbhai Aradhye Jayraj
Dhanjibhai PRAJAPATI Kaushik
Kumar Pal Ranjan
Pankajkumar PATHAK Sandeep
Rao Chitturi Trinadha
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of BR112022001285A2 publication Critical patent/BR112022001285A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022001285A 2019-07-22 2020-07-22 Degradador seletivo do receptor de estrogênio BR112022001285A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
BR112022001285A2 true BR112022001285A2 (pt) 2022-03-22

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001285A BR112022001285A2 (pt) 2019-07-22 2020-07-22 Degradador seletivo do receptor de estrogênio

Country Status (15)

Country Link
US (2) US11014915B2 (https=)
EP (1) EP4003525A1 (https=)
JP (1) JP2022541938A (https=)
KR (1) KR20220046586A (https=)
CN (1) CN114302879A (https=)
AU (1) AU2020317099A1 (https=)
BR (1) BR112022001285A2 (https=)
CA (1) CA3148592A1 (https=)
CL (1) CL2022000156A1 (https=)
IL (1) IL290036A (https=)
MX (1) MX2022001013A (https=)
PE (1) PE20221588A1 (https=)
PH (1) PH12022550182A1 (https=)
WO (1) WO2021014386A1 (https=)
ZA (1) ZA202201157B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) * 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
CN114127054B (zh) 2019-07-22 2024-04-09 勃林格殷格翰国际有限公司 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
CA3243621A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
CA2915534A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
US20160175284A1 (en) * 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
WO2017072792A1 (en) * 2015-10-27 2017-05-04 Sun Pharma Advanced Research Company Limited Novel heterocyclic antiestrogens
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
CL2022000156A1 (es) 2022-11-18
WO2021014386A1 (en) 2021-01-28
PE20221588A1 (es) 2022-10-10
JP2022541938A (ja) 2022-09-28
PH12022550182A1 (en) 2022-11-14
EP4003525A1 (en) 2022-06-01
KR20220046586A (ko) 2022-04-14
CA3148592A1 (en) 2021-01-28
US20210024504A1 (en) 2021-01-28
US11014915B2 (en) 2021-05-25
AU2020317099A1 (en) 2022-02-24
CN114302879A (zh) 2022-04-08
IL290036A (en) 2022-03-01
US20210261534A1 (en) 2021-08-26
MX2022001013A (es) 2022-02-22

Similar Documents

Publication Publication Date Title
BR112022001285A2 (pt) Degradador seletivo do receptor de estrogênio
UA122528C2 (uk) Сполуки, які модулюють fxr (nr1h4)
EP4212532A3 (en) Mitragynine analogs and uses thereof
BR112023022836A2 (pt) Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
MA54091A (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
JOP20200231B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
MY210112A (en) Processes and compounds
EA202191566A1 (ru) Соединения, модулирующие fxr (nr1h4)
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
BR112017024555A2 (pt) moduladores de ccr2
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
GEP20217227B (en) Novel phenyl derivatives
EP3784123A4 (en) MEDICAL SYSTEM FOR THERAPY ADJUSTMENT
EA201991622A1 (ru) Комплексная терапия для лечения рака
BR112021024726A2 (pt) Novos derivados bicíclicos
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
MA41389A1 (fr) Utilisation de sulfones tricycliques en tant que modulateurs de rory
BR112021020372A2 (pt) Métodos de tratamento de linfoma não hodgkin ao usar 2-(2,6-dioxopiperidin-3-il)-4-((2-fluo ro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoin dolina-1,3-diona
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
WO2020106461A3 (en) Anti-mertk antibodies and methods of use thereof
EP4428147A3 (en) Activin receptor type iia variants and methods of use thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.